Abstract: Techniques involve: acquiring a first source snapshot for a source storage object stored in a source storage device; determining first difference data between the first source snapshot and the source storage object or a second source snapshot for the source storage object, creation time of the first source snapshot being associated with creation time of the second source snapshot; and sending the first difference data to a destination storage device to enable the destination storage device to create a first destination snapshot for a destination storage object stored in the destination storage device based on the first difference data. Such techniques can migrate snapshots more efficiently to improve storage management efficiency.

Abstract: The disclosure relates to a pharmaceutical composition including daphnetin, a method for improving aortic endothelial cell function, and use of daphnetin in preparation of a medicine for improving aortic endothelial cell function. The daphnetin is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The daphnetin is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid.

Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

Abstract: The present invention provides for transgenic plants and methods of producing such transgenic plants, wherein the transgenic plants express an increased amounts of PYL9 to interact with abscisic acid (ABA) thereby activating enhanced drought resistance and leaf senescence relative to control or wild-type plants.

Abstract: The present disclosure discloses a novel compound, 3,4-dihydroxyphenethyl 3-hydroxybutanoate, a method for preparing the same and use of the same, and in particular, a compound of formula I, use of the compound of formula I, optically pure isomers of the compound, a mixture of enantiomers in any ratio, or pharmaceutically acceptable salts thereof in preparing health food and drug for relieving brain fatigue, improving learning and memory abilities, and ameliorating mania mood related to brain fatigue.

Abstract: The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.

Abstract: The disclosure relates to a pharmaceutical composition including daphnetin, a method for improving aortic endothelial cell function, and use of daphnetin in preparation of a medicine for improving aortic endothelial cell function. The daphnetin is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The daphnetin is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid.

Abstract: The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.

Abstract: The present disclosure provides a depth image processing method and apparatus, and an electronic device. The method includes: acquiring a first image acquired by a depth sensor and a second image acquired by an image sensor; determining a scene type according to the first image and the second image; and performing a filtering process on the first image according to the scene type.

Abstract: The present disclosure discloses use of hydroxytyrosol acetate in preparation of a medicament for improving aortic endothelial cell function. The hydroxytyrosol acetate is capable of inhibiting an inflammation of aortic endothelial cells caused by a saturated fatty acid, reducing mRNA levels corresponding to matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and plasma plasminogen activator inhibitor-1 (PAI-1) in aortic endothelial cells and protecting mitochondria from being damaged by inflammation of aortic endothelial cells caused by a saturated fatty acid, preventing the occurrence and development of atherosclerosis by anti-inflammatory and protecting mitochondrial function.

Abstract: A tissue chip core-making system based on image recognition and positioning and a core-making method thereof—includes a cutting system and a computer control system. The cutting system includes a numerical control cutting machine, XYZ-axis translation worktables, a 360° rotation turntable, a recipient wax block rack, a freezing table and an image recognition and positioning module. A core-making process based on the core-making system includes: lofting, sample position recognition, tissue sample image acquisition, tissue sample image processing, cutting parameter setting, tissue sample cutting, tissue core information recognition and storage to obtain a tissue core with information traceability. The method obtains a coring region through visual recognition, and has the characteristics of high automation degree and high work efficiency.

Abstract: The present disclosure relates to use of daphnetin in preparation of composition for improving cognitive ability, particularly discloses use of daphnetin in preparation of a composition for preventing or treating disorders caused by increased ?-amyloid level, and use of daphnetin as an inhibitor of ?-amyloid. The present disclosure also relates to use of daphnetin in preparation of a composition for preventing or treating cognitive disorders, which are the Alzheimer's disease and Parkinson's disease.

Abstract: Disclosed are a diglycosylated benzophenoxazine photosensitizer, and a preparation method and use thereof. The present invention greatly improves the enriched concentration of the photosensitizer in tumor cells by taking full advantage of the enhanced uptake and enhanced glycolysis of carbohydrates by tumor cells and the glycosylation of a selenium-containing benzophenoxazine compound, thereby improving the targeting of a diglycosylated benzophenoxazine photosensitizer involved in the present invention in the treatment of cutaneous tumors and also significantly decreasing the toxic and side effects of the photodynamic therapy. The present invention can efficiently and rapidly inhibit the proliferation of cells of cutaneous squamous cell carcinoma and essentially cause no damage to normal cells.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: The present invention discloses a device and method for achieving a core part press-down technology in a continuous casting round billet solidification process. The device includes a plurality of round billet radial press-down devices distributed along an axial array of round billets outside a press-down interval of the round billets. The press-down interval is an area from 0.65 of a solid phase ratio of the round billets to solidification end points. Each round billet radial press-down device comprises a plurality of press-down rollers. A forming hole for extruding the round billets is formed between the press-down rollers. Two adjacent round billet radial press-down devices are arranged in the manner of staggering. The device can effectively solve the defect problems of porosity, segregation and the like in the core of the continuous casting round billets, the yield of the continuous casting round billets is increased, and the production cost is reduced.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Abstract: The present disclosure provides an ultraviolet LED epitaxial production method and an ultraviolet LED, where the method includes: pre-introducing a metal source and a group-V reactant on a substrate, to form a buffer layer through decomposition at a first temperature; growing an N-doped AlwGa1-wN layer on the buffer layer at a second temperature; growing a multi-section LED structure on the N-doped AlwGa1-wN layer at a third temperature, wherein a number of sections of the multi-section LED structure is in a range of 2 to 50; and each section of the LED structure comprises an AlxGa1-xN/AlyGa1-yN multi-quantum well structure and a P-doped AlmGa1-mN layer, and the multi-section LED structure emits light of one or more wavelengths, which realizes that a single ultraviolet LED emits ultraviolet light of different wavelengths, thereby improving the luminous efficiency of the ultraviolet LED.

Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

Abstract: The present disclosure discloses an image sensor, an imaging device, a mobile terminal and an imaging method. The image sensor comprises a photosensitive pixel array and a filer arranged on the photosensitive pixel array. The filter comprises a filer unit array comprised a plurality of filter units, wherein each filter unit covers N photosensitive pixels, and some of the filter units comprise white filter areas. The white filter areas cover at least one of the N photosensitive pixels of the N photosensitive pixels, wherein a merged pixel is formed by the N photosensitive pixels covered by the same filter unit, wherein N is a positive integer.

Abstract: The disclosure relates to a composition for improving aortic endothelial cell function and use thereof. The composition includes acetic acid, lactic acid, polyoxyethylene castor oil, and disodium alkyl polyoxyethylene sulfosuccinate. The composition is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by saturated fatty acids, increasing a mitochondrial respiration and metabolism of vascular endothelial cells, and preventing an occurrence and progression of atherosclerosis. The composition is capable of reducing human aortic endothelial inflammation caused by saturated fatty acids, for example, reducing the mRNA levels of interleukin-6 (IL-6) and matrix metalloproteinase-1 (MMP-1), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by saturated fatty acids, for example, increasing the expression of mitochondrial complexes I and III and mitochondrial metabolism-associated Foxo1.